Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX:PBT)
Filing Type: Form 6-K (Foreign Private Issuer)
Reporting Period: Half-year ended 31 December 2011
Filing Date: 24 February 2012
Business Overview: Prana is a development-stage medical biotechnology company focused on research into Alzheimer's Disease (AD), Huntington's Disease (HD), and Parkinson's Disease (PD). The company is not yet generating revenue from product sales; its primary activities involve research and development (R&D) and clinical trials.
Key Financial Metrics
| Metric | Half-Year Ended 31 Dec 2011 | Half-Year Ended 31 Dec 2010 |
|---|---|---|
| Revenue (Continuing Operations) | $110,266 | $70,310 |
| Other Income | $762,861 | $0 |
| Net Loss | ($3,369,841) | ($3,833,093) |
| Loss Per Share (Basic & Diluted) | (1.20) cents | (1.59) cents |
| Cash and Cash Equivalents | $6,747,177 | $2,881,555 |
| Net Tangible Assets Per Security | 1.93 cents | 2.52 cents (as at 30 June 2011) |
| Total Liabilities | $2,071,919 | $2,079,750 (as at 30 June 2011) |
Note: Revenue consists entirely of interest received on bank accounts. Other income includes R&D tax concessions and grants.
Material Changes vs. Prior Period
- Revenue Growth: Revenue from continuing operations increased by 56.83% to $110,266, driven by higher interest income due to increased cash balances.
- Loss Reduction: The net loss decreased by 12.09% to $3,369,841. This improvement is primarily attributed to significant "Other Income" of $762,861, which was absent in the prior period.
- Other Income Components: The $762,861 in other income comprised a $696,965 R&D Tax Concession and a $65,896 grant from the Michael J. Fox Foundation.
- R&D Expenses: Research and development expenses increased to $2,075,697 (excluding personnel) from $1,535,868 in the prior period, reflecting intensified clinical trial activities.
- Cash Position: Cash and cash equivalents decreased by approximately $2.1 million during the period due to operating outflows, though the absolute cash balance remains significantly higher than the prior year-end due to equity raises.
Outlook, Management Commentary, and Risks
Operational Highlights
- Parkinson's Disease (PBT434): Received a grant from the Michael J. Fox Foundation for pre-clinical characterization. A Notice of Allowance for pharmaceutical compositions containing PBT434 was issued by the USPTO in November 2011.
- Huntington's Disease (PBT2): Entered a contract with the University of Rochester for a Phase IIa trial involving 100 patients. The trial design is a double-blinded study administering PBT2 or placebo.
- Alzheimer's Disease (PBT2): Commenced patient screening for the "IMAGINE" Phase II imaging trial (12 months) supported by the Alzheimer's Drug Discovery Foundation. The study utilizes PET imaging to assess beta-amyloid deposits.
- Scientific Grants: Researchers received NHMRC grants to study PBT2's role in age-related cognitive impairment and excitotoxicity.
Liquidity and Capital Raising
- ATM Facility: The company utilizes an "at-the-market" (ATM) facility to sell American Depositary Receipts (ADRs). As of 31 December 2011, it sold 1,011,013 ADRs for gross proceeds of ~$1.87 million.
- Subsequent Events: In January and February 2012, the company sold an additional 966,924 ADRs for gross proceeds of ~$1.55 million.
- Going Concern: Directors believe the going concern basis is appropriate due to the ATM facility, ability to scale operations, and pursuit of alternative funding.
Risks and Contingencies
- Development Stage: The company expects to utilize cash until research activities become marketable.
- Contingent Liabilities: No change in contingent liabilities or assets since the last annual reporting date.
- Dividends: No dividends were declared for the period.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the current cash balance ($6.75M) against the operating loss of ~$3.4M per half-year and the pace of equity dilution via the ATM facility.
- Grant Reliance: Assess the impact of the $762k in non-operating income (tax concessions and grants) on the reported loss reduction; determine if this is recurring.
- Clinical Trial Milestones: Monitor the enrollment and preliminary data from the Huntington's Disease Phase IIa trial and the Alzheimer's "IMAGINE" imaging trial.
- Intellectual Property: Confirm the status of the PBT434 patent allowance and any potential regulatory hurdles for PBT2.
- Dilution: Review the total number of shares issued (285.7M) and outstanding options (29.2M) to understand potential future dilution.